September 29, 2022
RFA-NS-22-031 - Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to correct the Application and Submission Information in RFA-NS-22-031 "Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)". The following sentence, "Details of activities within active studies at the NeuroNEXT site is to be provided in an Appendix (see below)", was erroneously published in the Funding Opportunity Announcement (FOA). This notice removes this sentence from the FOA. Changes to the FOA are shown below.
Currently Reads:
Section IV. Application and Submission Information
PHS 398 Research Plan
Collaboration Plan
In the relevant sections, applicants must describe their ability to work in a collaborative and interactive manner with other Clinical Sites, the Clinical Coordinating Center, the Data Coordinating Center, and the NINDS and its partners in all aspects of the network program. Applicants are encouraged to describe any special group expertise or unique strengths of the team as a whole they can offer to the collaborative effort (e.g., team leadership and training, protocol adherence strategies, dissemination activities, recruitment strategies). Applicants must describe the potential pool of co-investigators at the site and their area of expertise. The applicant should indicate how co-investigators will be identified, motivated, and integrated into the network, and how the network team will support the co-investigators. A detailed plan must be included on collaboration with other clinical investigators at the Clinical Site. For sites already in the NeuroNEXT network, a description of the relevant accomplishments in the network, including participation in network committees, is to be included. Details of activities within active studies at the NeuroNEXT site is to be provided in an Appendix (see below).
Modified to Read:
Section IV. Application and Submission Information
PHS 398 Research Plan
Collaboration Plan
In the relevant sections, applicants must describe their ability to work in a collaborative and interactive manner with other Clinical Sites, the Clinical Coordinating Center, the Data Coordinating Center, and the NINDS and its partners in all aspects of the network program. Applicants are encouraged to describe any special group expertise or unique strengths of the team as a whole they can offer to the collaborative effort (e.g., team leadership and training, protocol adherence strategies, dissemination activities, recruitment strategies). Applicants must describe the potential pool of co-investigators at the site and their area of expertise. The applicant should indicate how co-investigators will be identified, motivated, and integrated into the network, and how the network team will support the co-investigators. A detailed plan must be included on collaboration with other clinical investigators at the Clinical Site. For sites already in the NeuroNEXT network, a description of the relevant accomplishments in the network, including participation in network committees, is to be included.
All other aspects of this FOA remain unchanged.
Joan Ohayon, RN, MSN, CRNP, MSCN
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Email: ohayonj@ninds.nih.gov
and Human Services (HHS)
